Welcome to our dedicated page for AN2 Therapeutics SEC filings (Ticker: ANTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The AN2 Therapeutics, Inc. (Nasdaq: ANTX) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. AN2 describes itself as a clinical-stage biopharmaceutical company developing novel small molecule therapeutics from its boron chemistry platform, with programs in Chagas disease, melioidosis, NTM lung disease caused by Mycobacterium abscessus, and oncology targets.
Periodic and current reports such as Forms 10-K, 10-Q, and 8-K provide detail on AN2’s research and development expenses, cash position, and progress across its pipeline. For example, recent Form 8-K filings reference press releases reporting quarterly financial results, including operating expenses and net loss, and describe how the company is advancing clinical trials and collaborations. These documents help investors understand how AN2 funds and prioritizes its infectious disease and oncology programs.
Regulatory filings can also disclose capital structure changes. A Form 8-K describes AN2’s issuance of pre-funded warrants in exchange for common stock to an institutional investor, including key terms such as exercise price and beneficial ownership limitations. Such filings give insight into how the company structures financing while managing ownership thresholds.
On this page, users can access AN2’s annual reports (Form 10-K) and quarterly reports (Form 10-Q) once filed, along with current reports (Form 8-K) that cover material events, collaborations, and financial updates. AI-powered summaries on Stock Titan are designed to highlight the main points in lengthy filings, helping readers quickly identify items related to clinical development, cash runway, or capital transactions without reading every line.
Investors interested in AN2’s ongoing work in Chagas disease, melioidosis, NTM lung disease, tuberculosis collaborations, and oncology targets can use the filings page to review the company’s official disclosures and track how its boron chemistry platform is reflected in its regulatory reporting.
AN2 Therapeutics, Inc. is asking stockholders to vote at its 2026 Annual Meeting on June 3, 2026, at 8:00 a.m. Pacific Time in Menlo Park, California. Investors will elect three Class I directors to terms running until the 2029 annual meeting and ratify PricewaterhouseCoopers LLP as independent auditor for fiscal 2026. Stockholders of record at the close of business on April 15, 2026, when 35,995,545 common shares were outstanding and entitled to vote, may cast votes by internet, telephone, mail, or in person. The proxy also details board structure, committee membership, executive compensation, equity awards, and severance and change-in-control protections for senior management.
AN2 Therapeutics, Inc. is registering 14,035,104 shares of common stock for resale by selling securityholders pursuant to a registration rights agreement. The amount comprises 8,245,611 issued shares and 5,789,493 shares issuable upon exercise of pre-funded warrants. The company is not selling any shares and will receive no proceeds from resales; however, upon exercise of the pre-funded warrants AN2 will receive the nominal cash exercise price paid by holders.
AN2 Therapeutics is offering up to $80,000,000 of common stock in an at‑the‑market (ATM) program under a sales agreement with Jefferies LLC. Shares may be sold from time to time at market prices through Jefferies acting as agent or principal; Jefferies may receive up to 3.0% of gross proceeds as compensation. The prospectus supplement ties this $80,000,000 ATM to the company’s existing $300,000,000 shelf registration.
For context, AN2 had 27,413,171 shares outstanding as of December 31, 2025; subsequent private placements sold 8,245,611 shares and pre‑funded warrants to purchase up to 5,789,493 shares. The company states net proceeds are intended to fund research and development, working capital and general corporate purposes.
Aziz Kabeer reported acquisition or exercise transactions in this Form 4 filing.
AN2 Therapeutics director Aziz Kabeer received 3,775 shares of Common Stock as an equity grant. The shares were issued in lieu of cash under the non-employee director compensation policy and vest immediately. Following this award, he holds 56,254 shares directly.
Separate from his direct holdings, 1,995,958 shares are held by Adjuvant Global Health Technology Fund, L.P. and 377,542 shares are held by Adjuvant Global Health Technology Fund DE, L.P. Mr. Kabeer is affiliated with these entities and may be deemed to share voting and dispositive power, but each person and entity disclaims beneficial ownership except for any pecuniary interest.
Marks Gilbert Lynn reported acquisition or exercise transactions in this Form 4 filing.
AN2 Therapeutics director Gilbert Lynn Marks received a stock grant of 3,775 shares of Common Stock on April 10, 2026. The shares were issued in lieu of cash under the company’s non-employee director compensation policy and carry a grant price of $0.00 per share.
All 3,775 shares vest immediately, meaning Marks has full ownership without a vesting schedule. Following this award, he directly holds a total of 79,084 shares of AN2 Therapeutics common stock. This is a compensation-related grant, not an open-market purchase.
AN2 Therapeutics, Inc. director Patricia A. Martin received a grant of common stock as part of non-employee director compensation. She acquired 1,192 shares at a price of $0.00 per share, issued in lieu of cash fees, and now directly holds 18,097 shares. According to the disclosure, all of the awarded shares vest immediately.
AN2 Therapeutics filed a shelf registration to offer up to $300,000,000 of securities and registered resale of up to 14,035,104 shares of common stock by selling securityholders. The filing carries forward $209,983,747.80 of unsold securities from an earlier registration and includes an $80,000,000 at-the-market sales agreement with Jefferies.
The prospectus states the company will not receive proceeds from resales by the selling securityholders and that any issuer sales under the sales agreement will be on a continuous, market-driven basis. The prospectus supplements will specify exact terms, proceeds treatment and any selling-holder identities.
AN2 Therapeutics, Inc. entered an Open Market Sale Agreement with Jefferies that allows it to issue and sell, from time to time, up to $80 million of its common stock through at-the-market offerings under a Form S-3 shelf registration.
Jefferies will act as sales agent and receive a commission of up to 3.0% of gross proceeds. On the same date, AN2 terminated its prior TD Cowen at-the-market program, under which it had already sold 2,502,000 shares for aggregate proceeds of $20,016,251.